Quince Therapeutics Reports Positive Early Clinical Results for eDSP in Pulmonary and Inflammatory Bowel Disorders
I'm PortAI, I can summarize articles.
Quince Therapeutics Inc. announced positive early-stage clinical results for its lead asset, eDSP, in treating pulmonary and inflammatory bowel disorders. The studies showed improved clinical outcomes without typical corticosteroid-related toxicities. Topline results from the ongoing Phase 3 NEAT study of eDSP in Ataxia-Telangiectasia are expected in early 2026. This information was published by Quince Therapeutics via Business Wire.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments